title: Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.
abstract: Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.
authors.affiliation: Institute of Cardiology and Center of Excellence on Aging, "G. d'Annunzio" University-Chieti, C/o Ospedale SS. Annunziata, Chieti, Italy. rdecater@unich.it.
authors.forename: Raffaele
authors.identifier: 0000-0003-1637-574X
authors.initials: R
authors.lastname: De Caterina
authors.affiliation: Department of Clinical and Experimental Medicine, University of Insubria and Ospedale di Circolo, Varese, Italy.
authors.forename: Walter
authors.initials: W
authors.lastname: Ageno
authors.affiliation: Cardiology Division, Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Boriani
authors.affiliation: Division of Cardiology, Hospital Policlinico of Bari, Bari, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Colonna
authors.affiliation: Department of Internal Medicine I, Angiology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
authors.forename: Angelo
authors.initials: A
authors.lastname: Ghirarduzzi
authors.affiliation: Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Patti
authors.affiliation: Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.
authors.forename: Roberta
authors.initials: R
authors.lastname: Rossini
authors.affiliation: Laboratory of Interventional Cardiology, Division of Cardiology, Ospedale Maggiore, Bologna, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Rubboli
authors.affiliation: Thrombosis Unit and Hemophilia Center, Department of Oncology, Città della Salute e della Scienza-Molinette hospital, Turin, Italy.
authors.forename: Piercarla
authors.initials: P
authors.lastname: Schinco
authors.affiliation: Vascular and Emergency Medicine and Stroke Unit, University of Perugia, Perugia, Italy.
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Agnelli
mesh_terms: D000367:Age Factors; D000925:Anticoagulants / Q000494:pharmacology; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D057186:Comparative Effectiveness Research; D006801:Humans; D054539:Medication Therapy Management; D017410:Practice Guidelines as Topic; D011725:Pyridines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control; D014859:Warfarin / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D011725:Pyridines; D013844:Thiazoles; D014859:Warfarin; C552171:edoxaban
keywords: Atrial fibrillation; Edoxaban; Non-vitamin K antagonist oral anticoagulants; Oral anticoagulants; Venous thromboembolism; Vitamin K antagonists